Clinicopathological Analysis of Hepatocellular Adenoma According to New Bordeaux Classification: Report of Eight Korean Cases
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Hepatocellular adenoma (HCA) is a rare benign tumor of the liver. A subtype classification of HCA (hepatocyte nuclear factor 1α [HNF1α]-mutated, β-catenin-mutated HCA, inflammatory HCA, and unclassified HCA) has recently been established based on a single institutional review of a HCA series by the Bordeaux group. Methods: We used histologic and immunohistochemical parameters to classify and evaluate eight cases from our institution. We evaluated the new classification method and analyzed correlations between our results and those of other reports. Results: Seven of our eight cases showed histologic and immunohistochemical results consistent with previous reports. However, one case showed overlapping histologic features, as previously described by the Bordeaux group. Four cases showed glutamine synthetase immunohistochemical staining inconsistent with their classification, indicating that glutamine synthetase staining may not be diagnostic for β-catenin-mutated HCA. HNF1α-mutated HCA may be indicated by the absence of liver fatty acid binding protein expression. Detection of amyloid A may indicate inflammatory HCA. HCA with no mutation in the HNF1α or β-catenin genes and no inflammatory protein expression is categorized as unclassified HCA. Conclusions: Although the new classification is now generally accepted, validation through follow-up studies is necessary.
Abstract
Background: Hepatocellular adenoma (HCA) is a rare benign tumor of the liver. A subtype classification of HCA (hepatocyte nuclear factor 1α [HNF1α]-mutated, β-catenin-mutated HCA, inflammatory HCA, and unclassified HCA) has recently been established based on a single institutional review of a HCA series by the Bordeaux group. Methods: We used histologic and immunohistochemical parameters to classify and evaluate eight cases from our institution. We evaluated the new classification method and analyzed correlations between our results and those of other reports. Results: Seven of our eight cases showed histologic and immunohistochemical results consistent with previous reports. However, one case showed overlapping histologic features, as previously described by the Bordeaux group. Four cases showed glutamine synthetase immunohistochemical staining inconsistent with their classification, indicating that glutamine synthetase staining may not be diagnostic for β-catenin-mutated HCA. HNF1α-mutated HCA may be indicated by the absence of liver fatty acid binding protein expression. Detection of amyloid A may indicate inflammatory HCA. HCA with no mutation in the HNF1α or β-catenin genes and no inflammatory protein expression is categorized as unclassified HCA. Conclusions: Although the new classification is now generally accepted, validation through follow-up studies is necessary.
참고문헌 (27)
- Edmondson HA, "Liver-cell adenomas associated with use of oral contraceptives", N Engl J Med, 294, pp.470~472 (1976)
- Rooks JB, "Epidemiology of hepatocellular adenoma: the role of oral contraceptive use", JAMA, 242, pp.644~648 (1979)
- Foster JH, "Familial liver-cell adenomas and diabetes mellitus", N Engl J Med, 299, pp.239~241 (1978)
- Lee DY, "Reproductive health characteristics of urban South Korean women", Gynecol Obstet Invest, 70, pp.154~159 (2010)
- Kim SH, "Microsurgical reversal of tubal sterilization: a report on 1,118 cases", Fertil Steril, 68, pp.865~870 (1997)
- Zucman-Rossi J, "Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC", Hepatology, 43, pp.515~524 (2006)
- Bioulac-Sage P, "Genotype phenotype classification of hepatocellular adenoma", World J Gastroenterol, 13, pp.2649~2654 (2007)
- Bioulac-Sage P, "Subtype classification of hepatocellular adenoma", Dig Surg, 27, pp.39~45 (2010)
- Bluteau O, "Bi-allelic inactivation of TCF1 in hepatic adenomas", Nat Genet, 32, pp.312~315 (2002)
- Bacq Y, "Familial liver adenomatosis associated with hepatocyte nuclear factor 1alpha inactivation", Gastroenterology, 125, pp.1470~1475 (2003)
- Bioulac-Sage P, "Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience", Hepatology, 50, pp.481~489 (2009)
- Bioulac-Sage P, "Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update", J Hepatol, 46, pp.521~527 (2007)
- Bioulac-Sage P, "Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry", Hepatology, 46, pp.740~748 (2007)
- Dokmak S, "A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas", Gastroenterology, 137, pp.1698~1705 (2009)
- Cadoret A, "New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism", Oncogene, 21, pp.8293~8301 (2002)
- Zucman-Rossi J, "Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas", Oncogene, 26, pp.774~780 (2007)
- Bioulac-Sage P, "Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver", Gastroenterology, 128, pp.1211~1218 (2005)
- Paradis V, "Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma", Gastroenterology, 126, pp.1323~1329 (2004)
- 김동환, "A Case of Hepatocellular Carcinoma Within Hepatocellular Adenoma in a Non-Cirrhotic Male", The Korean Journal of Internal Medicine, 24(2), pp.147~152 (2009), 대한내과학회
- Chen YW, "p53 gene and Wnt signaling in benign neoplasms: beta-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia", Hepatology, 36(4 Pt 1), pp.927~935 (2002)
- Bioulac-Sage P, "Immunohistochemical markers on needle biopsies are helpful for the diagnosis of focal nodular hyperplasia and hepatocellular adenoma subtypes", Am J Surg Pathol, 36, pp.1691~1699 (2012)
- Rebouissou S, "HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response element-binding protein (ChREBP) activation", J Biol Chem, 282, pp.14437~14446 (2007)
- van Aalten SM, "Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice", J Hepatol, 55, pp.120~125 (2011)
- Sasaki M, "Characterization of hepatocellular adenoma based on the phenotypic classification: The Kanazawa experience", Hepatol Res, 41, pp.982~988 (2011)
- Terris B, "Close correlation between beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas", Oncogene, 18, pp.6583~6588 (1999)
- Fattet S, "Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics", J Pathol, 218, pp.86~94 (2009)
- Bellamy CO, "The value of immunophenotyping hepatocellular adenomas: consecutive resections at one UK centre", Histopathology, 62, pp.431~445 (2013)